NTC Strengthens Ophthalmology Portfolio with Pharmathen Acquisition and Global Market Expansion NTC has completed the acquisition of Pharmathen's ophthalmology business, significantly enhancing its glaucoma segment and international reach.

NTC Strengthens Ophthalmology Portfolio with Pharmathen Acquisition and Global Market Expansion #Italy #Milan #NTC #Pharmathen #Wise_Equity

NTC's Acquisition of Pharmathen's Ophthalmology Division Signifies Strategic Growth in the Market NTC S.r.l. has successfully acquired Pharmathen’s ophthalmology sector, reinforcing its position in the glaucoma treatment market and expanding its international reach.

NTC's Acquisition of Pharmathen's Ophthalmology Division Signifies Strategic Growth in the Market #Italy #Milan #Pharmathen #Wise_Equity #NTC_S.r.l.

NTC Finalizes Acquisition of Pharmathen's Ophthalmology Business Fueled by Wise Equity NTC S.r.l. enhances its presence in the ophthalmology sector with the acquisition of Pharmathen's glaucoma business, supported by Wise Equity.

NTC Finalizes Acquisition of Pharmathen's Ophthalmology Business Fueled by Wise Equity #Italy #Milan #Pharmathen #NTC_Pharma #Wise_Equity

NTC Completes Acquisition of Pharmathen's Ophthalmology Operations with Wise Equity's Backing NTC S.r.l.'s acquisition of Pharmathen's ophthalmology business marks a strategic expansion, enhancing its product line and global footprint.

NTC Completes Acquisition of Pharmathen's Ophthalmology Operations with Wise Equity's Backing #Italy #Milan #Pharmathen #NTC_Pharma #Wise_Equity

Neuraxpharm and Pharmathen partner to develop long-acting injectable therapies - Pf Media Neuraxpharm and Pharmathen have announced a strategic alliance to co-develop new long-acting injectable therapies.

#mentalhealth #CNSdisorders #Neuraxpharm #Pharmathen #longactinginjectabletherapies #LATT #psychiatry #LATTprogram #shortactingdosageforms #prescribers #patientcompliance #LAI #LAIproducts #CNSproducts #CNSpatients #establishedtherapies #patientchoice
pf-media.co.uk/news/neuraxp...

Neuraxpharm and Pharmathen Collaborate on Injectable Therapies for CNS Disorders Neuraxpharm and Pharmathen team up for developing long-acting injectable therapies aimed at enhancing treatment for CNS disorders, promoting patient compliance.

Neuraxpharm and Pharmathen Collaborate on Injectable Therapies for CNS Disorders #Neuraxpharm #Pharmathen #CNS #Barcelona,_Düsseldorf,_Athens